Introduction {#Sec1}
============

Transcatheter aortic valve replacement (TAVR) has become an established treatment for patients with symptomatic, severe aortic stenosis with intermediate, high, or prohibitive surgical risk \[[@CR1]--[@CR5]\]. Despite advances in patient selection, operator experience, and valve delivery systems, ischemic and bleeding complications remain important concerns after TAVR, as they are associated with increased morbidity and mortality \[[@CR6]--[@CR8]\]. However, limited data are available comparing long-term outcomes with varying antithrombotic regimens after TAVR.

Current guidelines recommend dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (for 1--6 months) after TAVR in patients with no indication for therapeutic oral anticoagulation (OAC). In patients with an indication for OAC, guidelines generally recommend against the use of triple therapy \[[@CR9]--[@CR12]\]. However, these recommendations have been made empirically and vary amongst professional societies, leading to heterogeneity in clinical practice \[[@CR13]\].

We sought to examine the association between different antithrombotic regimens and the risk of mortality, ischemic, and bleeding outcomes in a non-selected clinical population undergoing TAVR. Specifically, we compared outcomes among TAVR patients prescribed single or dual antiplatelet therapy (AP), a single antiplatelet agent plus OAC (SAC), or triple therapy (TT) with dual antiplatelet therapy (DAPT) and OAC.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

We retrospectively analyzed consecutive patients who underwent TAVR at Brigham and Women's Hospital in Boston, Massachusetts, from April 2009 through March 2014. Baseline medical history, routine laboratory testing, electrocardiography, echocardiography, CHA2DS2-VASc score, ATRIA score, New York Heart Association functional classification, pre-procedure antithrombotic regimen, and TAVR procedural characteristics were collected. Patients were then prospectively followed for ascertainment of study outcomes. The Institutional Review Board of Partners Healthcare in Boston, Massachusetts, approved the study, and signed informed consent was obtained from each patient. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Antithrombotic Regimen {#Sec4}
----------------------

The antithrombotic regimen was noted pre-TAVR, at the time of discharge from TAVR admission, at 30 days, at 1 year, and through April 2016 using electronic health records and telephone follow-up. Antithrombotic regimens were classified as single or dual antiplatelet therapy only (AP), single antiplatelet plus anticoagulant therapy (SAC), or triple therapy (TT) with DAPT plus OAC. Patients were grouped according to the antithrombotic regimen at the time of latest follow-up for the purposes of the statistical analysis.

Outcomes {#Sec5}
--------

The primary endpoint was the composite of death, myocardial infarction (MI), stroke, or major bleeding (requiring hospitalization, life-threatening, or fatal). Outcomes were assessed according to Valve Academic Research Consortium-2 definitions \[[@CR14]\] at discharge, 30 days, 1 year, and through April 2016 using electronic medical record data and telephone follow-up with a standardized questionnaire.

Statistical Analysis {#Sec6}
--------------------

To determine associations between antithrombotic therapy group and the primary composite outcome, a Cox proportional hazards model was used. A multivariable model was developed with best subset variable selection methods using bootstrap resampling in order to account for model variation due to small sample size \[[@CR15]\]. The final model included adjustment for chronic lung disease, prior percutaneous coronary intervention (PCI), male sex, age, and low-gradient aortic stenosis (defined as left ventricular ejection fraction \< 50%, aortic valve area \< 1.0 cm^2^, and mean aortic valve gradient \< 40 mmHg). Results are reported as adjusted hazard ratios (HR) and 95% confidence intervals (CI). Proportional hazards assumption for the final model was assessed by score tests using scaled Schoenfeld residuals. Crude cumulative event rates were calculated by the complement of Kaplan--Meier survival estimates, and log-rank test *p* values are also reported. All reported *p* values are two-sided, and significance level was set at alpha 0.05. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

Table [1](#Tab1){ref-type="table"} outlines the baseline characteristics of each study group. A total of 246 patients underwent TAVR from April 2009 to March 2014. Of these, five patients were excluded for the following reasons: prescribed no antithrombotic therapy (*n* = 2) and incomplete post-discharge follow-up (*n* = 3), leaving 241 patients for final analysis. The baseline characteristics among the AP (*n* = 133), SAC (*n* = 88), and TT (*n* = 20) groups were similar, with the exception of rates of atrial fibrillation or flutter (*p* \< 0.01), indication for OAC (*p* \< 0.01), aortic valve mean gradient (*p* = 0.044), and aortic valve peak velocity (*p* = 0.047) (Table [1](#Tab1){ref-type="table"}). Overall, 67.2% of cases were done with a transfemoral approach, while 16.2% and 15.8% of cases were performed via a transapical and transaortic approach, respectively.Table 1Patient characteristics by study groupAP (*n* = 133)SAC (*n* = 88)TT (*n* = 20)Overall (*n* = 241)*p* valueAge (years)80.9 ± 10.081.0 ± 7.980.9 ± 6.380.9 ± 9.00.68Male sex, *n* (%)63 (47.4)53 (60.2)12 (60)128 (53.1)0.14BMI (kg/m^2^)26.6 ± 7.428.2 ± 5.928.1 ± 5.327.3 ± 6.80.053Atrial fibrillation or flutter, *n* (%)31 (23.3)72 (81.8)14 (70)117 (48.5)\< 0.001Prior DVT/PE,*n* (%)9 (6.8)11 (12.5)2 (10)22 (9.1)0.35CHA2DS2-VASc score5.2 ± 1.35.5 ± 1.25.7 ± 1.15.4 ± 1.30.10ATRIA score2.7 ± 1.02.7 ± 0.83.1 ± 0.82.7 ± 0.90.20Indication for OAC,*n* (%)40 (30.1)76 (86.4)16 (80)132 (54.8)\< 0.001Prior GI bleeding,*n* (%)23 (17.3)9 (10.2)4 (20)36 (14.9)0.28Dyslipidemia,*n* (%)105 (78.9)72 (81.8)20 (100)197 (81.7)0.076Hypertension,*n* (%)117 (88)81 (92)20 (100)218 (90.5)0.19Diabetes mellitus,*n* (%)52 (39.1)37 (42)7 (35)96 (39.8)0.82Prior PCI,*n* (%)37 (27.8)25 (28.4)9 (45)71 (29.5)0.28Peripheral arterial disease,*n* (%)30 (22.6)19 (21.6)6 (30)55 (22.8)0.72Cerebrovascular disease,*n* (%)14 (10.5)16 (18.2)4 (20)34 (14.1)0.20Chronic lung disease,*n* (%)49 (36.8)41 (46.6)8 (40)98 (40.7)0.35On hemodialysis,*n* (%)5 (3.8)2 (2.3)1 (5)8 (3.3)0.76NYHA class,*n* (%)0.86 I0 (0)1 (1.2)0 (0)1 (0.4) II7 (5.7)5 (5.9)2 (10.5)14 (6.2) III82 (66.7)55 (64.7)11 (57.9)148 (65.2) IV34 (27.6)24 (28.2)6 (31.6)64 (28.2)LVEF (%)52.9 ± 15.054.4 ± 14.255.3 ± 16.853.7 ± 14.80.60Aortic valve area (cm^2^)0.6 ± 0.20.7 ± 0.20.7 ± 0.10.7 ± 0.20.65Aortic valve mean gradient (mmHg)47.0 ± 13.841.7 ± 12.343.1 ± 15.644.8 ± 13.60.045Aortic valve peak velocity (m/s)4.4 ± 0.64.2 ± 0.64.3 ± 0.84.3 ± 0.60.047Low gradient AS^a^,*n* (%)24 (18)11 (12.5)2 (10)37 (15.4)0.42Moderate or severe MR,*n* (%)47 (38.5)33 (38.4)7 (36.8)87 (38.3)0.99Valve sheath access site *n* (%)0.41 Transfemoral93 (69.9)56 (63.6)13 (65)162 (67.2) Transapical15 (11.3)20 (22.7)4 (20)39 (16.2) Transaortic24 (18)11 (12.5)3 (15)38 (15.8) Other1 (0.8)1 (1.1)0 (0)2 (0.8)Continuous variables are presented as mean ± standard deviation*AP* antiplatelet therapy, *SAC* single antiplatelet plus oral anticoagulant therapy, *TT* triple therapy, *BMI* body mass index, *DVT* deep venous thrombosis, *PE* pulmonary embolism, *ATRIA* anticoagulation and risk factors in atrial fibrillation, *OAC* oral anticoagulation, *GI* gastrointestinal, *PCI* percutaneous coronary intervention, *NYHA* New York Heart Association, *LVEF* left ventricular ejection fraction, *AS* aortic stenosis, *MR* mitral regurgitation^a^Defined as aortic valve mean gradient \< 40 mmHg, left ventricular ejection fraction \< 50%, and aortic valve area \< 1 cm^2^

Of the 241 patients followed for a median of 2.1 years (interquartile range, 0.7--2.9 years), 53.5% (*n* = 129) had at least one endpoint. The components of the composite outcome in the cohort were distributed as death (68%), major bleeding (23%), stroke (6%), and MI (3%) at 2-year follow-up. The risk of the composite outcome was highest with TT (70%; HR 2.88, 95% CI 1.61--5.16, *p* = 0.0004) and intermediate with SAC (42%; HR 1.66, 95% CI 1.13--2.42, *p* = 0.009), compared to AP (31%) at 2 years (Fig. [1](#Fig1){ref-type="fig"}). Mortality rates at 2 years were 61%, 32%, and 26% (*p* = 0.005) in the TT, SAC, and AP groups, respectively, while major bleeding rates were 29%, 18%, and 9.1%, respectively (*p* = 0.02). Rates of stroke and MI were low and similar among groups.Fig. 1Kaplan--Meier time-to-event curves for the primary composite endpoint of death, myocardial infarction, stroke, or major bleeding stratified by treatment group. *TAVR* transcatheter aortic valve replacement, *HR* hazard ratio, *CI* confidence interval, *AP* antiplatelet therapy, *SAC* single antiplatelet plus anticoagulant therapy, *TT* triple therapy

A total of 132 patients in the cohort had an indication for OAC (88.6% had atrial fibrillation or flutter), including 40 in the AP group, 76 in the SAC group, and 16 in the TT group. Among patients with an indication for OAC, the composite outcome occurred in 69% of TT, 38% of SAC, and 38% of AP patients (*p* = 0.06) at 2-year follow-up.

Discussion {#Sec8}
==========

This study evaluated the association between post-TAVR antithrombotic regimen and the composite outcome of death, MI, stroke, or major bleeding in a single-center cohort of 241 consecutive patients with at least 2-year follow-up. Patients treated with TT or SAC versus AP had a higher incidence of the composite outcome, even after multivariate adjustment. This finding was driven by an increase in both mortality and major bleeding in the TT and SAC groups.

TAVR patients are at high risk for both ischemic and bleeding events by virtue of co-morbidities and the procedure itself. Both types of complications are associated with increased morbidity and mortality. Moreover, TAVR patients frequently undergo pre-emptive coronary artery stenting, which necessitates DAPT, and approximately half have atrial fibrillation requiring OAC. Given this complex interplay, identifying an antithrombotic regimen that achieves an optimal balance between ischemic protection and bleeding risk mitigation is paramount in this patient population. Nevertheless, guideline recommendations for antithrombotic therapy after TAVR remain empiric, and are extrapolated from the PCI experience and early TAVR clinical trial protocols \[[@CR16]\].

Our analysis indicates that treatment with TT or SAC is associated with adverse clinical outcomes compared to treatment with AP alone after TAVR, which is consistent with findings from other studies of patients undergoing TAVR \[[@CR17], [@CR18]\] and surgical aortic valve replacement \[[@CR19]\]. We did not observe a benefit on ischemic endpoints with regimens using 2 or 3 antithrombotics compared to AP alone, as rates of MI and stroke were similar among the three treatment groups, but the study was not powered to do so. In addition to higher rates of bleeding with TT and SAC, we observed a higher mortality rate with these treatment strategies compared to AP. Importantly, our analysis shows that these effects persisted over a period of 2 years. However, while bleeding is reduced when fewer antithrombotic agents are used, omitting an anticoagulant in patients with atrial fibrillation (or another indication for OAC) significantly increases the risk of thromboembolism, which often has more serious clinical consequences than bleeding.

The relatively low number of patients, especially in the TT group, is an important limitation of our study. Additionally, patients in the TT and SAC groups had higher rates of atrial fibrillation/flutter and an indication for OAC, which could have led to confounding by indication despite our use bootstrap resampling. Patients were categorized based on antithrombotic regimen at the latest time of follow-up, and results could differ if an intention-to-treat analysis was carried out. The patients we studied represent a high-risk cohort, as evidenced by the large burden of co-morbidities and high 2-year mortality rate. Thus, our results may not be applicable to lower-risk patients. Lastly, our study is observational in nature, and randomized trials are needed to determine the optimal antithrombotic regimen after TAVR in patients with and without an indication for anticoagulation. The recently reported aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation (ARTE) trial demonstrated that aspirin monotherapy reduced risk of bleeding, without increasing the risk of MI or stroke, compared to DAPT in TAVR patients \[[@CR20]\]. Ongoing trials include ATLANTIS (NCT02664649), AUREA (NCT01642134), AVATAR (NCT02735902), ENVISAGE-TAVR (NCT02943785), GALILEO (NCT02556203), POPular-TAVI (NCT02247128), and TICTAVR (NCT02817789). The results of these trials will likely inform future guidelines and clinical decision-making.

Conclusions {#Sec9}
===========

In a consecutive series of patients from our institution undergoing TAVR between 2009 and 2014, treatment with triple therapy or a single antiplatelet agent plus an oral anticoagulant was associated with an increased risk of the composite of death, MI, stroke, or major bleeding at 2 years compared to treatment with antiplatelet therapy alone, even after multivariable adjustment. Further prospective investigations to determine the optimal antithrombotic regimen in TAVR patients are awaited.
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